Abstract:BACKGROUND & OBJECTIVE:Increasing evidences showed that circulating tumor metastasis related factors could be detected, and it is related to tumor stage, and prognosis. This study was to investigate the correlation of serum vascular endothelial growth factor (sVEGF), CD44 standard (CD44s), and matrix metalloproteinase-3 (MMP-3) level to the clinical outcomes in nasopharyngeal carcinoma (NPC)patients.METHODS:Forty-six NPC patients without metastasis, 20 NPC patients with local recurrence and/or distant metastasis,and 28 healthy controls entered this study. Serum VEGF, CD44s, and MMP-3 protein were quantitatively analyzed by enzyme-link immunosorbent assay (ELISA).RESULTS:The mean level of sVEGF in metastatic NPC was (791.7+/-560.5) ng/L, which was significantly higher than that in NPC patients without metastasis [(429.0+/-249.7) ng/L], and healthy controls [(424.6+/-197.1) ng/L], whereas there was no significant difference between NPC patients without metastasis and healthy controls. In primary NPC patients, sVEGF level in NPC of stage T4 were significantly higher than those in NPC of stage T1-T3. Moreover, 2-year disease-free survival rate in patients with sVEGF level of more than 600 ng/L was significantly lower than that in patients with sVEGF Level of less than 600 ng/L (37.5% vs 83.9%). The serum level of MMP-3 in NPC patients with metastasis [(28.8+/-15.5)microg/L] was significantly higher than that in patients without metastasis [(19.8+/-11.6) microg/L], and healthy controls [(16.2+/-11.1) microg/L], but there was no significant difference between NPC patients without metastasis and healthy controls. Though the serum level of CD44s in NPC patients (including patients with or without metastasis) was higher than that in healthy controls, there was no significant difference between NPC patients with and without metastasis. No correlation was observed between serum MMP-3, CD44s level and clinical outcomes of NPC.CONCLUSION:Our results indicate that when the sVEGF level are >or= 800 ng/L and/or serum MMP-3 level >or= 30 microg/L in NPC patients, local recurrence or distant metastasis would occur. In primary NPC patients without metastasis, sVEGF level is correlate with primary tumor progression, moreover, sVEGF level of >or= 600 ng/L before treatment predicate lower 2-year disease-free survival rate.

Measurement of Serum Neopterin and Soluble Lymphocyte Antigens(sCD4 and sCD8) in Patients with Nasopharyngeal Carcinoma and Its Clinical Significance

[Expression and Significance of Serum Sicam-1 and Scd4 & Scd8 in Patients with Nasopharyngeal Carcinoma].

Changes of serum concentrations of neopterin in patients with nasopharyngeal carcinoma

[Detection of EBV-LMP1 antibodies in sera and clinical significance in the patients with nasopharyngeal carcinoma].

Detection of Serum Interleukin-10 Levels in Nasopharyngeal Carcinoma

[Scd40l, Sp-Selectin and Sicam-1 Plasma Levels in Nasopharyngeal Carcinoma].

Analysis of the Expression of Surface Receptors on NK Cells and NKG2D on Immunocytes in Peripheral Blood of Patients with Nasopharyngeal Carcinoma

Detection and clinical significance of circulating tumor cells in peripheral blood of nasopharyngeal cancer patients with modified immunomagnetic enrichment and fluorescent immunocytochemistry

Associations of serum CD 62 P and IL-6 levels with nasopharyngeal carcinoma staging and prognosis

CD4+CD25high Regulatory Cells in Peripheral Blood of NSCLC Patients

High Expression of NLR and SII in patients With Nasopharyngeal Carcinoma as Potential Prognostic Observations

[Clinical Significance of Quantitative Analysis of Serum VEGF, CD44s, and MMP-3 Protein in Nasopharyngeal Carcinoma].

Serum Angiogenin Concentration in Nasopharyngeal Carcinoma Patients and Its Clinical Significance

Detection of circulating tumor cells in peripheral blood of patients with nasopharyngeal carcinoma and evaluate its prognostic value

Treatment-Related Lymphopenia is Possibly a Marker of Good Prognosis in Nasopharyngeal Carcinoma: a Propensity-Score Matching Analysis

[Quantitative Analysis of Plasma Epstein-Barr Virus (EBV) DNA for Monitoring of Recurrence and Metastasis in Nasopharyngeal Carcinoma Patients after Radiotherapy].

Quantitative Analysis of Epstein-Barr Virus DNA in Plasma and Peripheral Blood Cells in Patients with Nasopharyngeal Carcinoma

Gene expression profile of immune cells from patients with nasopharyngeal carcinoma of stage T3-4N0]

Novel Potential Markers of Nasopharyngeal Carcinoma for Diagnosis and Therapy

Clinical Value of Combined Detection of Tumor Markers for Nasopharyngeal Carcinoma and Squamous Cell Carcinoma in Head and Neck

Novel potential markers of nasopharyngeal carcinoma for diagnosis and therapy.